Articles

Gastrointestinal infections were the most common serious infections associated with biologics, according to a cohort analysis.

Biologics for Psoriasis May Increase Serious Infection Risk

John Jesitus is a medical writer based in Westminster, CO.

Addressing underdiagnosis, underrepresentation, and undertreatment in skin of color patients with psoriasis.

Psoriasis Strategies in Skin of Color

Engage patients in treatment compliance and lifestyle changes to achieve optimal outcomes.
 

Mastering Game Changers in Psoriasis  

Sol-Gel has announced pre-clinical data on SGT-510, its roflumilast drug, for the treatment of psoriasis. 

Sol-Gel Announces New Data for SGT-510 for Psoriasis

The FDA announces it did not meet the June 25 PDUFA action date on the sNDA for active psoriatic arthritis treatment, upadacitinib.

FDA Fails to Provide Approval Decision on Upadacitinib for PsA 

COSMOS phase 3b study data demonstrated the effectiveness of guselkumab in patients diagnosed with psoriatic arthritis. 

Guselkumab Demonstrates Efficacy in Phase 3b Study

The National Psoriasis Foundation has updated its guidance statements for individuals living with psoriatic disease during the COVID-19 pandemic.

NPF COVID-19 Task Force Issues Updated Guidance Statements

The pro-inflammatory transcription factor is critical for the expression of IL-23, which is known to play a role in psoriasis.

C-Jun Protein Linked to Psoriasis

Biologic therapy has proven very useful in treating an increasing number of dermatologic diseases and conditions. However, caution is warranted for patients with chronic infectious diseases. 

Dangers, Benefits of Biologics Must Be Carefully Weighed

Videos

John Browning, MD, FAAD, FAAP, MBA, discusses the impact of the recent FDA approval of secukinumab (Cosentyx, Novartis) for the treatment of moderate to severe plaque psoriasis in children and adolescents.